Detalhe da pesquisa
1.
Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells.
PLoS Pathog
; 19(12): e1011853, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38100526
2.
Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-ß.
J Immunol
; 208(1): 169-180, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34853077
3.
Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.
Hepatology
; 69(5): 2061-2075, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30561769
4.
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.
Blood
; 122(6): 863-71, 2013 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23770775
5.
TCR affinity and specificity requirements for human regulatory T-cell function.
Blood
; 119(15): 3420-30, 2012 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22318202
6.
The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor.
Mol Cancer Ther
; 6(7): 2081-91, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17620437
7.
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
Nat Med
; 21(8): 914-921, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26193344
8.
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
Sci Transl Med
; 5(197): 197ra103, 2013 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-23926201
9.
Production of a soluble disulfide bond-linked TCR in the cytoplasm of Escherichia coli trxB gor mutants.
Mol Biotechnol
; 45(2): 140-9, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20143183
10.
Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.
J Immunol
; 180(9): 6116-31, 2008 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18424733
11.
High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines.
J Immunol
; 179(9): 5845-54, 2007 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17947658